Soy Isoflavones (Genistein, Daidzein, Glycitein)
Soy isoflavones are a family of phytoestrogen polyphenols — chiefly genistein, daidzein, and glycitein — found in soybeans. They have been studied for menopausal hot flushes and bone health. Effects in randomised trials are modest and inconsistent, partly because individual response depends on the gut microbiome's ability to convert daidzein to the more bioactive metabolite equol — only about 25–30 % of Western adults are equol producers. Soy isoflavones have no authorised UK health claim, and the safety profile carries a specific concern in oestrogen-sensitive cancers.
Camden Medicals editorial · Last reviewed 2 May 2026 · Next review May 2027
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Botanical
- Typical daily dose
- Trials of menopausal symptoms have most commonly used 40–100 mg of total isoflavones per day, taken for at least 12 weeks. Lower doses (≤30 mg/day) approximate Western dietary intake; higher doses (>120 mg/day) do not have stronger evidence.
- Top use evidence
- Limited
On this page
What it is
Soy isoflavones are a sub-class of polyphenols (specifically, isoflavonoids) that occur naturally in soybeans (Glycine max) and other legumes. The three main soy isoflavones are genistein (typically the most abundant, ~50 % of total), daidzein (~40 %), and glycitein (~10 %). In whole soybeans they exist mostly as glycosides (genistin, daidzin, glycitin); intestinal bacteria cleave the sugar in the gut to release the active aglycones.
Daidzein is further metabolised by certain gut bacteria into equol — a more bioactive, longer-half-life metabolite with stronger oestrogen-receptor-β affinity. Only roughly 25–30 % of Western adults are equol producers (the prevalence is higher, ~50–60 %, in traditional-soy-diet East Asian populations). Equol-producer status is one reason soy isoflavone trials show heterogeneous individual responses.
Commercial soy isoflavone supplements are typically standardised extracts from soybean germ or whole soybean, declared as total isoflavone milligrams. Dose-equivalence between extract preparations is not perfectly consistent because aglycone vs glycoside content varies; published trials commonly use 40–100 mg total isoflavones per day.
At a glance
- A phytoestrogen family from soybeans — genistein, daidzein, glycitein. Bind oestrogen receptors with much weaker affinity than human oestradiol.
- No UK-authorised health claim. EFSA evaluation on hold; pending claim "maintains bone mineralisation in post-menopausal women" is not authorised.
- Best-studied use is menopausal hot flushes — Cochrane CD001395 reports modest effect that does not consistently exceed placebo across all subgroups.
- Equol-producer status (~25–30 % of Western adults) shapes individual response. Trials of equol directly are more consistent than trials of soy isoflavones.
- Avoid in oestrogen-sensitive cancers (breast, endometrial) without specialist advice. Talk to your prescriber if you take tamoxifen, aromatase inhibitors, or thyroid medication.
What people use it for
Post-menopausal women with bothersome hot flushes who want to try a non-hormonal option
Cochrane CD001395 (Lethaby 2013) reports modest, inconsistent reductions in hot flush frequency and severity with soy isoflavones at 40–100 mg/day. Effects are smaller than with HRT and may take 6–12 weeks to manifest. Some trials are positive, some null. Equol-producer status correlates with stronger response in subgroup analyses. [2]
Some evidenceLimitedPost-menopausal women considering soy isoflavones for bone health
Evidence base is mixed and has not yielded an authorised UK Article 14 reduction-of-disease-risk claim. Calcium + vitamin D + adequate physical activity remain the foundation interventions; isoflavones are not a replacement for HRT or bisphosphonates where clinically indicated.
Some evidenceLimitedAnyone with a personal or strong family history of breast, endometrial, or ovarian cancer
Talk to your oncologist or breast-care nurse before starting. Population-cohort data on dietary soy in East Asian women is reassuring, but supplemental concentrated isoflavones are a different exposure. UK Cancer-survivorship guidance is conservative; specialist input is needed. [6]
Popular, not provenInsufficientAnyone on tamoxifen, aromatase inhibitors, or thyroid medication
Mechanism overlap (ER binding) means soy isoflavones could in principle interfere with tamoxifen / aromatase-inhibitor therapy. Soy may also reduce thyroxine absorption. Talk to your prescriber.
Some evidenceLimited
How it works
Isoflavones are selective oestrogen-receptor modulators (SERMs): they bind both oestrogen receptor-α and -β with much weaker affinity than endogenous 17β-oestradiol (about 1/1,000 to 1/100 of oestradiol). They preferentially activate ER-β, which is more abundant in bone, brain, and the cardiovascular system, while being weaker at ER-α (more abundant in breast and uterus). In a low-oestrogen environment (post-menopausal), they produce mild oestrogenic effects; in a high-oestrogen environment, they may compete with endogenous oestradiol and produce mild anti-oestrogenic effects. The bone, vasomotor, and cancer-risk debate hinges on this dual behaviour and on equol-producer status.
Common myths
Myth"Soy gives men breasts (gynaecomastia)."
RealityAt dietary intakes (and at typical supplement doses), no. Isoflavones bind oestrogen receptors with ~1/1,000th the affinity of endogenous oestradiol; they do not aromatise testosterone. Case reports of gynaecomastia at extreme intake (multiple litres of soya milk daily for months) exist but are not representative of typical intake. Soy is consumed daily by large male populations in East Asia without population-level gynaecomastia.
Myth"Soy isoflavones are equivalent to HRT."
RealityThey are not. Effect sizes on hot flushes are smaller than HRT, and the bone, vasomotor, and cardiovascular evidence base is weaker. Soy isoflavones are an option for women who do not want or cannot have HRT, not a substitute when HRT is medically indicated. [2]
Myth""Natural" oestrogen from soy is risk-free."
RealityPhytoestrogens are bioactive on oestrogen receptors. The debate about safety in oestrogen-sensitive cancer is unresolved for supplemental concentrated isoflavones. "Natural" is not a clinical-reasoning standard.
Common online questions
Synthesised from the questions UK shoppers most often ask online about Soy Isoflavones (Genistein, Daidzein, Glycitein). Each answer is editorial and links to its evidence in the Sources list below.
Will soy isoflavones help my hot flushes?
Trial results are mixed, with modest reductions on average and wide individual variation. Equol-producer status — whether your gut bacteria convert daidzein to the more active equol metabolite — is one factor; only about a quarter to a third of Western adults are equol producers. Trials at 40–100 mg total isoflavones per day for 12 weeks typically show effects if they are going to. If your symptoms are severe and affecting daily life, talk to your GP about the fuller menopause-care pathway including HRT options. [2,1]
I had ER-positive breast cancer — is soy safe?
Talk to your oncologist or breast-care nurse first. The evidence on supplemental concentrated isoflavones in women with ER-positive breast cancer is not strong enough for a confident self-treatment recommendation. Dietary soy in food (tofu, edamame, soya milk) is a different exposure and is generally regarded as compatible with post-cancer diets in NHS / cancer-charity guidance. [6]
Do I need to space soy isoflavones from my levothyroxine?
Yes — separate doses by at least 4 hours. Soy can reduce levothyroxine absorption, sometimes requiring a dose adjustment. Tell your prescriber if you start regular soy supplementation; next TFT bloods may need timing care.
Is soy in supplements the same as soy in food?
Concentrated extracts deliver substantially higher milligram amounts of total isoflavones than typical UK food intake. East Asian dietary soy intake (often cited at 25–50 mg/day total isoflavones) is reached without supplementation. Higher supplemental doses (60–120 mg/day) are common in trials. The dose ceiling for safety is not formally set in UK guidance.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Menopausal vasomotor symptoms (hot flushes, night sweats)
LimitedEvidencelimitedCochrane CD001395.pub4 (Lethaby 2013, then 2017 updates) pooled 43 RCTs of phytoestrogens vs placebo. Modest reductions in hot flush frequency reported but with significant heterogeneity and a substantial placebo response. Subsequent trials of S-equol directly (the active gut metabolite) have shown more consistent effects, supporting the equol-producer hypothesis. Effects are smaller than with HRT; soy is not a like-for-like substitute for women whose symptoms warrant medical-grade therapy. [2]
Bone mineral density in post-menopausal women
LimitedEvidencelimitedTrials report small benefits in BMD with isoflavone supplementation over 1–2 years; effect sizes are smaller than with bisphosphonates. No authorised UK Article 14 claim. The pending EFSA claim on bone mineralisation in post-menopausal women remains unauthorised.
Cardiovascular risk markers
LimitedEvidencelimitedModest LDL-cholesterol reductions reported (~3–4 %); meaningful clinical event-reduction not established. Not a substitute for statins where clinically indicated.
Breast cancer risk / outcomes
MixedEvidencemixedPopulation-cohort data on dietary soy in East Asian women is broadly reassuring or modestly protective; data on supplemental concentrated isoflavones in Western post-menopausal women is less clear. Specific concern around isoflavones in women with oestrogen-receptor-positive breast cancer or on tamoxifen warrants oncologist supervision rather than self-treatment.
Safety
Soy isoflavones are generally well tolerated at typical food-supplement doses. Talk to a clinician before use if you have an oestrogen-sensitive condition, a personal or strong family history of breast / endometrial / ovarian cancer, take tamoxifen / aromatase inhibitors, take levothyroxine, or are pregnant. Dietary soy is a different and generally lower exposure.
Talk to your pharmacist or GP first if you:
- You have a personal or strong family history of breast, endometrial, or ovarian cancer.
- You take tamoxifen, aromatase inhibitors, or other endocrine cancer therapy.
- You take levothyroxine or other thyroid medication — soy reduces absorption; separate doses by at least 4 hours.
- You are pregnant, breastfeeding, or trying to conceive.
- You are giving to a child — paediatric use is not standard.
- You have a soy allergy — contraindicated.
Common side effects: Mild GI symptoms (bloating, wind) in a minority. Allergic reactions in soy-allergic individuals.
Pregnancy and breastfeeding
Insufficient safety data on supplemental isoflavone concentrates in pregnancy. Dietary soy in food is a different exposure and is generally regarded as compatible with pregnancy.
Insufficient data; avoid supplemental concentrated isoflavones during breastfeeding.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Soy allergy.
- Active oestrogen-receptor-positive breast cancer (without specialist advice).
- Active endometrial hyperplasia or unexplained vaginal bleeding (without medical assessment).
Drug interactions
- Levothyroxine — reduces absorption. Separate dose by ≥4 hours.
- Tamoxifen, aromatase inhibitors — theoretical mechanism overlap on ER binding; oncologist supervision required.
- Warfarin — minor; isoflavones may modestly affect INR. Flag use to anticoagulation team.
- MAOIs — theoretical risk via tyramine in fermented soy products; not relevant to isolated isoflavone extracts.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- Mild GI symptoms — bloating, wind, soft stools.
Rare side effects
- Allergic reactions in soy-allergic individuals.
- Endometrial hyperplasia at high doses over long periods (>5 years) — small case-series signal; not consistent across larger trials.
How to take it
- Typical supplemental range
- Trials of menopausal symptoms have most commonly used 40–100 mg of total isoflavones per day, taken for at least 12 weeks. Lower doses (≤30 mg/day) approximate Western dietary intake; higher doses (>120 mg/day) do not have stronger evidence.
- Timing
- No specific timing requirement. Separate from levothyroxine doses by at least 4 hours.
How to spot quality
Look for
- Total isoflavone milligrams declared per serving — not just "soy extract Xmg".
- Aglycone-equivalent or glycoside content disclosed when possible.
- Source soybean origin (non-GMO is a common consumer expectation).
- GMP-certified manufacture; allergen statement (soy is one of the 14 declarable allergens).
Red flags
- Isoflavone content not declared — only "soy extract" with a milligram figure that says nothing about active content.
- Marketing implies HRT-equivalent effect, "natural hormone replacement", or oestrogen-sensitive cancer prevention.
- Combined with synthetic hormone-active substances at unspecified doses.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Flaxseed (Linum usitatissimum) — whole seed, oil, and lignans
Limited evidencePhytoestrogen cluster — soy genistein / daidzein + flaxseed lignan-enterolactone overlap on weak-estrogen signalling.
Soy isoflavones (genistein, daidzein, glycitein) bind ERβ at low affinity; flaxseed lignans (secoisolariciresinol diglucoside, SDG) are converted by gut bacteria to enterolactone, also a weak phytoestrogen. Mechanism complementary on phytoestrogen axis.
Evidence: Camden flaxseed covers phytoestrogen cluster.
Doses studied: 40-80 mg soy isoflavones + 1-2 tbsp ground flaxseed daily.
Sage (Salvia officinalis)
Limited evidenceMenopause-cluster pairing — see Camden sage.
Sage cholinergic / hot-flush mechanism + soy isoflavones phytoestrogen.
Evidence: Camden sage covers cluster.
Doses studied: 40-80 mg soy isoflavones + 300 mg sage extract daily.
Calcium (Ca)
Limited evidencePostmenopausal bone-health cluster — soy isoflavones bone-mineral framing + calcium-vitamin D Article 14 disease-risk-reduction claim.
Soy isoflavones have observational and small-RCT bone-mineral signals via weak-estrogen ERβ binding; calcium + vitamin D delivers UK Article 14 reduction-of-disease-risk claim for postmenopausal bone-mineral loss. Mechanism complementary.
Evidence: Camden calcium covers cluster.
Doses studied: 40-80 mg soy isoflavones + 1000 mg calcium + 800 IU vitamin D3 daily (postmenopausal context).